Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Roberto S. Oliveri"'
Autor:
Antonio Uccelli, Alice Laroni, Lou Brundin, Michel Clanet, Oscar Fernandez, Seyed Massood Nabavi, Paolo A. Muraro, Roberto S. Oliveri, Ernst W. Radue, Johann Sellner, Per Soelberg Sorensen, Maria Pia Sormani, Jens Thomas Wuerfel, Mario A. Battaglia, Mark S. Freedman, on behalf of the MESEMS study group
Publikováno v:
Trials, Vol 20, Iss 1, Pp 1-13 (2019)
Abstract Background Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent inflammation and neurodege
Externí odkaz:
https://doaj.org/article/cecb42ab3b814fa7b6f5dace14d6516b
Publikováno v:
Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, Vol 25, Iss 1, Pp 1-12 (2017)
Abstract Background Management of the critically bleeding patient can be encountered in many medical and surgical settings. Common for these patients is a high risk of dying from exsanguination secondary to developing coagulopathy. The purpose of thi
Externí odkaz:
https://doaj.org/article/ab7c54f393974e438c5d2d8ad1dfff3c
Publikováno v:
Neurobiology of Disease, Vol 62, Iss , Pp 338-353 (2014)
Traumatic spinal cord injury (SCI) is a devastating event with huge personal and societal costs. A limited number of treatments exist to ameliorate the progressive secondary damage that rapidly follows the primary mechanical impact. Mesenchymal stem
Externí odkaz:
https://doaj.org/article/b5205fd7edf24a3ea930be492086d248
Autor:
Tommy Li, Ida H. Hiemstra, Christopher Chiu, Roberto S. Oliveri, Brian Elliott, Dena DeMarco, Theodora Salcedo, Frederikke Lihme Egerod, Kate Sasser, Tahamtan Ahmadi, Manish Gupta
Publikováno v:
Clinical Pharmacology & Therapeutics. 112:1108-1119
Epcoritamab is a CD3xCD20 bispecific antibody (bsAb) that induces T-cell-mediated cytotoxicity against CD20-positive B cells. Target engagement and crosslinking of CD3 and CD20 (trimer formation) leads to activation and expansion of T cells and killi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5151e781ab00ccc5120d8c6f950d1fa4
https://doi.org/10.1002/cpt.2729
https://doi.org/10.1002/cpt.2729
Autor:
Antonio Uccelli, Alice Laroni, Rehiana Ali, Mario Alberto Battaglia, Morten Blinkenberg, Lou Brundin, Michel Clanet, Oscar Fernandez, James Marriott, Paolo Muraro, Seyed Massood Nabavi, Roberto S Oliveri, Ernst Radue, Cristina Ramo Tello, Irene Schiavetti, Johann Sellner, Per Soelberg Sorensen, Maria Pia Sormani, Jens Thomas Wuerfel, Mark S Freedman, Naser Aghdami, Eduardo Agüera-Morales, David Allan, Leila Arab, Mario Battaglia, Isabelle Berry, Bruno Bonetti, Chiara Capelli, Lucio Castellan, Maria Cellerino, Maria Teresa Cencioni, Giancarlo Comi, David Courtman, Francesco Dazzi, Anne Fischer-Nielsen, Victoria Fernandez, Mark S. Freedman, Roberto Furlan, Mario Gimona, Francesca Gualandi, Qingdong Guan, Ellen Iacobaeus, Matilde Inglese, Martino Introna, Guillermo Izquierdo, Shahedeh Karimi, Katarina Le Blanc, Sandra Loaiza, Shahrukh Mallik, Stephen Marley, Ruth Ann Marrie, James Marriot, Gianvito Martino, David Miller, Paolo A. Muraro, Richard Nicholas, Giovanni Orengo, Renuka Palanicawande, Matteo Pardini, Ernst W Radue, Carolina Rush, Luc Sensebe, Dirk Strunk, David Szwajcer, Claire Thalamas
Publikováno v:
LANCET NEUROLOGY
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Summary Background Mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells, have been proposed as a promising therapeutic option for people with multiple sclerosis on the basis of their immunomodulatory and neuroprotective properties.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a835d6b9db04107af54813a97700f6f0
https://doi.org/10.1016/s1474-4422(21)00301-x
https://doi.org/10.1016/s1474-4422(21)00301-x
Autor:
Rogier Mous, Ada Azaryan, Brian Elliott, Tommy Li, Dena DeMarco, Martine E.D. Chamuleau, Kim Linton, David John Lewis, Anna Sureda Balari, Roberto S. Oliveri, Pieternella J. Lugtenburg, Martin Hutchings, Michael Roost Clausen, Kuo mei Chen, Tahamtan Ahmadi, David Cunningham, Peter Johnson, Christopher Chiu
Publikováno v:
The Lancet, 398(10306), 1157-1169. Elsevier Limited
The Lancet, 398(10306), 1157-1169. Elsevier Ltd.
Hutchings, M, Mous, R, Clausen, M R, Johnson, P, Linton, K M, Chamuleau, M E D, Lewis, D J, Sureda Balari, A, Cunningham, D, Oliveri, R S, Elliott, B, DeMarco, D, Azaryan, A, Chiu, C, Li, T, Chen, K M, Ahmadi, T & Lugtenburg, P J 2021, ' Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma : an open-label, phase 1/2 study ', The Lancet, vol. 398, no. 10306, pp. 1157-1169 . https://doi.org/10.1016/S0140-6736(21)00889-8
Hutchings, M, Mous, R, Clausen, M R, Johnson, P, Linton, K M, Chamuleau, M E D, Lewis, D J, Sureda Balari, A, Cunningham, D, Oliveri, R S, Elliott, B, DeMarco, D, Azaryan, A, Chiu, C, Li, T, Chen, K, Ahmadi, T & Lugtenburg, P J 2021, ' Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma : an open-label, phase 1/2 study ', The Lancet, vol. 398, no. 10306, pp. 1157-1169 . https://doi.org/10.1016/S0140-6736(21)00889-8
Hutchings, M, Mous, R, Clausen, M R, Johnson, P, Linton, K M, Chamuleau, M E D, Lewis, D J, Sureda Balari, A, Cunningham, D, Oliveri, R S, Elliott, B, DeMarco, D, Azaryan, A, Chiu, C, Li, T, Chen, K M, Ahmadi, T & Lugtenburg, P J 2021, ' Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study ', The Lancet, vol. 398, no. 10306, pp. 1157-1169 . https://doi.org/10.1016/S0140-6736(21)00889-8
The Lancet, 398(10306), 1157-1169. Elsevier Ltd.
Hutchings, M, Mous, R, Clausen, M R, Johnson, P, Linton, K M, Chamuleau, M E D, Lewis, D J, Sureda Balari, A, Cunningham, D, Oliveri, R S, Elliott, B, DeMarco, D, Azaryan, A, Chiu, C, Li, T, Chen, K M, Ahmadi, T & Lugtenburg, P J 2021, ' Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma : an open-label, phase 1/2 study ', The Lancet, vol. 398, no. 10306, pp. 1157-1169 . https://doi.org/10.1016/S0140-6736(21)00889-8
Hutchings, M, Mous, R, Clausen, M R, Johnson, P, Linton, K M, Chamuleau, M E D, Lewis, D J, Sureda Balari, A, Cunningham, D, Oliveri, R S, Elliott, B, DeMarco, D, Azaryan, A, Chiu, C, Li, T, Chen, K, Ahmadi, T & Lugtenburg, P J 2021, ' Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma : an open-label, phase 1/2 study ', The Lancet, vol. 398, no. 10306, pp. 1157-1169 . https://doi.org/10.1016/S0140-6736(21)00889-8
Hutchings, M, Mous, R, Clausen, M R, Johnson, P, Linton, K M, Chamuleau, M E D, Lewis, D J, Sureda Balari, A, Cunningham, D, Oliveri, R S, Elliott, B, DeMarco, D, Azaryan, A, Chiu, C, Li, T, Chen, K M, Ahmadi, T & Lugtenburg, P J 2021, ' Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study ', The Lancet, vol. 398, no. 10306, pp. 1157-1169 . https://doi.org/10.1016/S0140-6736(21)00889-8
BACKGROUND: Patients with relapsed or refractory B-cell non-Hodgkin lymphoma have few treatment options. We aimed to establish the safety and recommended phase 2 dose of epcoritamab, a novel bispecific antibody that targets CD3 and CD20 and induces T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af475f2eb2549d35a7595f199ce1bd0f
https://research.vumc.nl/en/publications/f3dfa4ae-9861-4d28-8f31-26e4b87ec3e5
https://research.vumc.nl/en/publications/f3dfa4ae-9861-4d28-8f31-26e4b87ec3e5
Autor:
Tahamtan Ahmadi, W. ten Hagen, J. Blaedel, B. de Jong, E. Szafer‐Glusman, A.K. Sasser, Ida H. Hiemstra, Maria Jure-Kunkel, P. Garrido Castro, R. Snijdewint‐Nkairi, Danita H. Schuurhuis, M. Wielgos‐Bonvallet, Roberto S. Oliveri, C. W. Chiu, C. Kweekel, Esther C.W. Breij, B. Elliot
Publikováno v:
Hematological Oncology. 39
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::295c7501fdd87be41d8f79a81ba5781a
https://doi.org/10.1002/hon.78_2881
https://doi.org/10.1002/hon.78_2881
Autor:
David John Lewis, Rogier Mous, David Cunningham, Peter Johnson, Kuo-mei Chen, Martin Hutchings, Dena DeMarco, Anna Sureda Balari, Brian Elliott, Martine E.D. Chamuleau, Michael Roost Clausen, Kim Linton, Roberto S. Oliveri, Pieternella J. Lugtenburg
Publikováno v:
Annals of Oncology. 32:S292
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33fa2c8bb42af361d1148835a2d4367f
https://doi.org/10.1016/j.annonc.2021.05.546
https://doi.org/10.1016/j.annonc.2021.05.546
Autor:
Brian Elliot, Edith Szafer-Glusman, Wessel ten Hagen, Bart de Jong, Danita H. Schuurhuis, Christopher Chiu, Rajaa Snijdewint-Nkairi, A. Kate Sasser, Tahamatan Ahmadi, Julie Blaedel, Maria Jure-Kunkel, Roberto S. Oliveri, Esther C.W. Breij, Ida H. Hiemstra
Publikováno v:
Cancer Research. 81:1574-1574
B-cell non-Hodgkin lymphoma (B-NHL) is a heterogeneous disease with an unmet medical need for new efficacious, well tolerated, off-the-shelf therapies that can combine with standard of care (SOC) regimens. Epcoritamab (GEN3013; DuoBody®-CD3×CD20) i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::858e0d94f09b6063e784e8464115aba6
https://doi.org/10.1158/1538-7445.am2021-1574
https://doi.org/10.1158/1538-7445.am2021-1574
Autor:
Frederikke Lihme Egerod, Tommy Li, Theodora W. Salcedo, Manish Gupta, Christopher Chiu, Roberto S. Oliveri, Ida H. Hiemstra, Dena DeMarco
Publikováno v:
Blood. 136:35-36
Introduction: Epcoritamab (DuoBody-CD3×CD20) is a subcutaneously administered bispecific antibody (bsAb) that simultaneously binds to CD3 on T cells and CD20 on malignant B cells, resulting in T-cell activation and expansion and selective T-cell-med
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f17673b2dffec8b2e7a5e5bec72939f7
https://doi.org/10.1182/blood-2020-139457
https://doi.org/10.1182/blood-2020-139457